TABLE 2.
Sealants and adhesives used for clinical pulmonary applications
| Composition | Examples | Mechanism of action | Characteristics | References | |
| Lung volume reduction | |||||
| PVA | Aminated PVA Glutaraldehyde |
AeriSeal (PulmonX Corp, CA, USA) | Local delivery and in situ polymerisation induces inflammatory responses, fibrosis and scar tissue formation, promoting atelectasis | Degradable, and invokes inflammatory responses | [27, 29, 31] |
| Autologous blood | Autologous blood Fibrinogen Thrombin |
Blood clot formation is instigated at site which supports plugging of emphysematous tissue | Low cost, higher risk of infection and usually used as a last-resort treatment | [40–43] | |
| Sealing air/fluid leaks | |||||
| Fibrin | Fibrinogen Thrombin Factor XIII |
Vivostat Fibrin Sealant (Vivostat A/S Alleroed, Denmark); Tisseel (Baxter International, IL, USA) | Upon administration, fibrinogen is converted to fibrin in the presence of thrombin; fibrin forms clots which covalently bond with tissue with the help of factor XIII; this process is accelerated by addition of calcium ions | Neo-angiogenesis, normal wound healing, degradable, risk of disease transmission or allergic reactions as a derivative of human/animal plasma, unclear efficiency in wet environment and poor mechanical properties | [38, 44] |
| Cyanoacrylates | N-butyl cyanoacrylate Methacryloxysulpholane 2-octyl cyanoacrylate Butyl lactoyl cyanoacrylate |
Glubran2 (GEM, Tuscany, Italy); Omnex (Ethicon, NJ, USA) | Cyanoacrylates upon application polymerise in the presence of weak bases found in bodily fluids and blood including water and amines | Wet adhesion, rapid curing, low cost, inflammatory reactions induced, degradable, exothermic polymerisation and toxic byproducts | [45–47] |
| Albumin | Albumin Glutaraldehyde PEG |
BioGlue (CryoLife, GA, USA); Progel (BD, NJ, USA) | Lysine molecules in albumin, extracellular matrix, and cell surfaces crosslink upon glutaraldehyde exposure | Degradable, instigate inflammatory response, rigid, cytotoxic | [44, 48–51] |
| PEG | PEG Polylactic acid Polytrimethylene carbonate |
FocalSeal (Genzyme Corp, MA, USA); Coseal (Cohesion Technologies, CA, USA) |
PEG is modified with degradable functionalities or crosslinked with degradable polymers to confer adhesiveness and tissue bonding | Controlled degradation, flexibility, high adhesion strength and biocompatibility, high swelling ratio and low cohesive strength and brittleness | [38, 52] |
| Collagen | Collagen | Peri-Strips (Synovis Life Technologies, MN, USA) | Presents an adhesive matrix to provide additional clotting factors and to control bleeding; the matrix covalently binds to the tissue | Lower risk of disease transmission and composed of the most abundant extracellular matrix protein | [48] |
PVA: polyvinyl alcohol; PEG: polyethylene glycol.